Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials

被引:2
作者
Dayan, Davut [1 ]
Lukac, Stefan [1 ]
Rack, Brigitte [1 ]
Ebner, Florian [1 ,2 ]
Fink, Visnja [1 ]
Leinert, Elena [1 ]
Veselinovic, Kristina [1 ]
Schuetze, Sabine [1 ]
El Taie, Ziad [1 ]
Janni, Wolfgang [1 ]
Friedl, Thomas W. P. [1 ]
机构
[1] Univ Ulm, Dept Gynecol & Obstet, Prittwitzstr 43, D-89075 Ulm, Germany
[2] Gyn Freising, Freising Weihenstephan, Germany
关键词
Breast cancer; Invasive lobular carcinoma; No special type carcinoma; Survival; Lymph node infiltration; NEOADJUVANT CHEMOTHERAPY; LONG-TERM; RELATIVE EFFECTIVENESS; ADJUVANT CHEMOTHERAPY; DUCTAL CARCINOMA; PROGNOSIS; FEATURES;
D O I
10.1186/s13058-023-01750-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundInvasive lobular breast carcinomas (ILC) have different histological features compared to non-special type carcinomas (NST), but the effect of histological subtypes on survival is controversial. In this study, we compared clinicopathological characteristics and outcomes between ILC and NST based on a large pooled data set from three adjuvant breast cancer trials (SUCCESS A, B, and C) and investigated a potential differential effect of recurrence risk related to nodal stage on survival.MethodsFrom 2005 to 2017, the large randomized controlled SUCCESS A, B, and C trials enrolled 8190 patients with primary, intermediate-to-high-risk breast carcinoma. All patients received adjuvant chemotherapy, and endocrine and/or HER2-targeted treatment was given where appropriate. Survival outcomes in terms of disease-free survival (DFS), overall survival (OS), breast cancer-specific survival (BCSS), and distant disease-free survival (DDFS) were estimated using the Kaplan-Meier method and analyzed using log-rank tests as well as univariable and adjusted multivariable Cox regression models.ResultsIn the SUCCESS trials, 6284 patients had NST and 952 had ILC. The median follow-up time was 64 months. ILC patients were older, more likely to receive mastectomy, and more likely to have larger tumor sizes, lymph node infiltration, hormone receptor-positive, HER2neu-negative, and luminal A-like tumors than NST patients. In the overall cohort, no significant differences between ILC and NST were detectable regarding the four survival endpoints, with hazard ratios obtained in adjusted multivariable cox regressions of 0.96 (95% CI 0.77-1.21, p = 0.743) for DFS, 1.13 (95% CI 0.85-1.50, p = 0.414) for OS, 1.21 (95% CI 0.89-1.66, p = 0.229) for BCSS, and 0.95 (95% CI 0.73-1.24, p = 0.689) for DDFS. However, a differential effect of nodal stage on survival was observed, with better survival for ILC patients with pN0/pN1 tumors and worse survival for ILC patients with pN2/pN3 tumors compared to NST patients.ConclusionsOur results revealed that ILC was associated with worse survival compared to NST for patients at high risk of recurrence due to advanced lymph node infiltration. These findings should be taken into account for treatment decisions and monitoring.
引用
收藏
页数:15
相关论文
共 47 条
[1]   The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study [J].
Abel, Mary Kathryn ;
Shui, Amy M. ;
Melisko, Michelle ;
Chien, A. Jo ;
Yoshida, Emi J. ;
Lancaster, Elizabeth M. ;
Veer, Laura Van T. ;
Esserman, Laura J. ;
Mukhtar, Rita A. .
NPJ BREAST CANCER, 2021, 7 (01)
[2]   Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma [J].
Adachi, Yayoi ;
Ishiguro, Junko ;
Kotani, Haruru ;
Hisada, Tomoka ;
Ichikawa, Mari ;
Gondo, Naomi ;
Yoshimura, Akiyo ;
Kondo, Naoto ;
Hattori, Masaya ;
Sawaki, Masataka ;
Fujita, Takashi ;
Kikumori, Toyone ;
Yatabe, Yasushi ;
Kodera, Yasuhiro ;
Iwata, Hiroji .
BMC CANCER, 2016, 16
[3]  
awmf, S3-LL
[4]  
Azim HA, 2014, WOMENS HEALTH, V10, P511, DOI [10.2217/whe.14.48, 10.2217/WHE.14.48]
[5]   Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma [J].
Chen, Zheling ;
Yang, Jiao ;
Li, Shuting ;
Lv, Meng ;
Shen, Yanwei ;
Wang, Biyuan ;
Li, Pan ;
Yi, Min ;
Zhao, Xiao'ai ;
Zhang, Lingxiao ;
Wang, Le ;
Yang, Jin .
PLOS ONE, 2017, 12 (09)
[6]  
Cocquyt V, 2005, CURR OPIN OBSTET GYN, V17, P55
[7]   Outcome of special types of luminal breast cancer [J].
Colleoni, M. ;
Rotmensz, N. ;
Maisonneuve, P. ;
Mastropasqua, M. G. ;
Luini, A. ;
Veronesi, P. ;
Intra, M. ;
Montagna, E. ;
Cancello, G. ;
Cardillo, A. ;
Mazza, M. ;
Perri, G. ;
Iorfida, M. ;
Pruneri, G. ;
Goldhirsch, A. ;
Viale, G. .
ANNALS OF ONCOLOGY, 2012, 23 (06) :1428-+
[8]   Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes [J].
Cristofanilli, M ;
Gonzalez-Angulo, A ;
Sneige, N ;
Kau, SW ;
Broglio, K ;
Theriault, RL ;
Valero, V ;
Buzdar, AU ;
Kuerer, H ;
Buccholz, TA ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) :41-48
[9]   Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas [J].
Delpech, Y. ;
Coutant, C. ;
Hsu, L. ;
Barranger, E. ;
Iwamoto, T. ;
Barcenas, C. H. ;
Hortobagyi, G. N. ;
Rouzier, R. ;
Esteva, F. J. ;
Pusztai, L. .
BRITISH JOURNAL OF CANCER, 2013, 108 (02) :285-291
[10]   Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study [J].
Deniz, Miriam ;
DeGregorio, Amelie ;
DeGregorio, Nikolaus ;
Bekes, Inga ;
Widschwendter, Peter ;
Schochter, Fabienne ;
Ernst, Kristina ;
Scholz, Christoph ;
Bauer, Emanuel C. A. ;
Aivazova-Fuchs, Viktoria ;
Weissenbacher, Tobias ;
Kost, Bernd ;
Jueckstock, Julia ;
Andergassen, Ullrich ;
Steidl, Julia ;
Trapp, Elisabeth ;
Fasching, Peter A. ;
Haeberle, Lothar ;
Beckmann, Matthias W. ;
Schneeweiss, Andreas ;
Schrader, Iris ;
Janni, Wolfgang ;
Rack, Brigitte ;
Friedl, Thomas W. P. .
BREAST, 2019, 44 :81-89